生物标志物预测肾移植后移植物功能延迟及预后
研究在237例利兹移植患者(发现阶段)和319例英国7中心患者(验证阶段)中评估血清生物标志物对肾移植后DGF和预后的预测价值。由ACY1、sTNFR1和CysC组成的DGF线性预测因子AUROC在发现阶段为0.93,验证阶段降至0.83。多个生物标志物与死亡删失移植物生存相关,但预测模型未通过验证。
要点
- ACY1、sTNFR1和CysC联合预测DGF的AUROC在验证阶段为0.83。
- sTNFR1、CysC和Cr在发现与验证阶段均与DCGS显著相关。
- 基于CysC、ACY1、midkine和受者年龄的DCGS预测模型未通过验证。
核心结论
- 多个生物标志物在预测DGF或移植结局方面显示潜力,需进一步探索。
研究设计与样本
- 发现阶段纳入2003-2011年利兹移植的237例患者,验证阶段纳入2012-2016年英国7个移植中心的319例患者。
- 血清生物标志物检测时间:移植后第1-2天用于DGF预测,第1-3天用于预后评估。
- 发现阶段中位随访13.28年(IQR 12.4-13.8),验证阶段中位随访9.03年(IQR 5.19-10.16)。
主要发现
- DGF在发现队列中发生率为29.5%,验证队列为18.2%。
- ACY1、sTNFR1和CysC联合的DGF线性预测因子AUROC在发现阶段为0.93,验证阶段为0.83。
- 单个标志物预测DGF的AUROC(发现 vs 验证):ACY1 0.79 vs 0.65,sTNFR1 0.88 vs 0.89,CysC 0.89 vs 0.82,血清肌酐 0.75 vs 0.81。
- DCGS的线性预测变量包括CysC、ACY1、midkine和移植时受者年龄,k统计量在所有移植中为0.55,在尸体供肾移植中为0.52,未通过验证。
- sTNFR1、CysC和Cr在发现和验证阶段均与DCGS显著相关;ACY1和CysC在发生DGF的尸体供肾移植中与DCGS一致相关。
临床怎么用
- 联合ACY1、sTNFR1和CysC可在移植后早期辅助预测DGF风险。
- sTNFR1、CysC和Cr与DCGS相关,可用于预后评估参考。
局限性
- DCGS预测模型未通过验证,k统计量仅为0.55和0.52。
- 临床实践变化和生物标志物性能在兩阶段间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Aminoacylase-1 (ACY1) and additional biomarkers were evaluated for prediction of delayed graft function (DGF) and prognosis following kidney transplantation. METHODS: Serum biomarkers were measured (days 1-2 posttransplant for DGF prediction and 1-3 for prognosis) in 237 patients transplanted in Leeds (2003-2011) in the discovery phase, and 319 patients from 7 UK transplant centers (2012-2016) in the validation phase. Median follow-up was 13.28 years (interquartile range [IQR]: 12.4-13.8) and 9.03 years (IQR: 5.19-10.16), respectively. RESULTS: DGF occurred in 29.5% of discovery cohort patients and 18.2% of validation cohort patients. A DGF linear predictor combining ACY1, soluble tumor necrosis factor receptor-1 (sTNFR1) and cystatin C (CysC) demonstrated an area under the receiver operating characteristic (AUROC) of 0.93, decreasing to 0.83 during validation. Comparable values for the individual components were ACY1 (0.79 vs. 0.65), sTNFR1 (0.88 vs. 0.89), CysC (0.89 vs. 0.82), and 0.75 vs. 0.81 for serum creatinine (Cr) as the gold standard. The linear predictor variables for death-censored graft survival (DCGS) were CysC, ACY1, midkine, and recipient age at transplant, but k-statistic values of 0.55 in all transplants and 0.52 in deceased donor kidney transplants (DDKT) precluded validation. Individually, sTNFR1, CysC, and Cr were significantly associated with DCGS in both the discovery and validation phases. Preliminary findings indicated a consistent association of ACY1 and CysC with DCGS in DDKTs affected by DGF. Impacts of clinical practice changes and biomarker performance across the 2 phases are described. CONCLUSION: Several biomarkers show potential as predictors of DGF or outcome and should be explored further.
引用
- Banks RE, Wilson M, Welberry Smith M, et al. Biomarker Prediction of Delayed Graft Function and Prognosis Post-Kidney Transplantation. Kidney Int Rep. 2025. PMID: 41541788. doi:10.1016/j.ekir.2025.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。